NEWYou can now listen to Fox News articles!
A blood test that detects a protein linked to Alzheimer’s disease could help predict whether older adults will develop cognitive decline within five to 10 years, according to a new Mayo Clinic study published in JAMA Neurology.
The study examined levels of phosphorylated tau 217 (p-tau217) in 2,178 cognitively healthy adults aged 60 to 90 years. It also took into account age, gender and whether participants carried the APOE ε4 genetic variant, which is associated with the risk of Alzheimer’s disease.
Participants, drawn from the Mayo Clinic Aging Study and Alzheimer’s Disease Neuroimaging Initiative, underwent blood biomarker testing, genetic testing and multiple cognitive assessments.
SIGNS OF ALZHEIMER COULD APPEAR YEARS BEFORE MEMORY LOSS, STUDY SAY
While APOE ε4 had a modest association with risk after accounting for p-tau217, older age was associated with higher risk, the researchers found.
For example, at the same high level of p-tau217, a 65-year-old faced an estimated 6% five-year risk of mild cognitive impairment, compared to a 37% risk for an 85-year-old.

A blood test detecting a protein linked to Alzheimer’s disease could help predict whether older adults will develop cognitive decline within five to 10 years. (iStock)
Alzheimer’s disease is marked by plaques and tangles that build up in the brain, noted lead author Clifford Jack Jr., a neuroradiologist at the Mayo Clinic.
“The test tells you, just by taking a blood sample, whether someone has this pathology in the brain,” he told Fox News Digital, adding that higher levels of pathology are associated with a greater risk of progression from normal cognition to impairment.
10 HEALTH CONDITIONS CAN BE LINKED TO ALZHEIMER’S YEARS BEFORE DIAGNOSIS
Detecting p-tau217 in blood could be “less invasive and potentially more scalable” than using PET to measure amyloid burden, a hallmark of Alzheimer’s disease associated with future cognitive impairment.
“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” first author Alicia Algeciras-Schimnich, Ph.D., a medicine and pathology researcher at the Mayo Clinic Laboratory, said in a press release.

Alzheimer’s disease is characterized by plaques and tangles that build up in the brain. (iStock)
If experimental treatments prove effective in preventing or delaying cognitive decline, this blood test could take on greater importance, researchers say.
CLICK HERE TO SUBSCRIBE TO OUR HEALTH NEWSLETTER
“If preventative treatments become available, this type of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment,” Jack noted.
Limitations of the study
The risk estimates were developed as part of the Mayo Clinic Aging Study, which is based on a specific geographic area.
“The elderly population in southeastern Minnesota is not representative of the entire United States,” Jack said.
CLICK HERE FOR MORE HEALTH STORIES
Although the study’s methods can be applied to other populations, the researcher said the results need to be replicated outside the region.

The study does not establish that routine blood tests prevent dementia or improve clinical outcomes. (iStock)
The risk prediction model is not yet ready for routine screening of people without cognitive symptoms, according to the research team.
“There are no approved treatments for people who are (asymptomatic) but have the brain disease,” Jack told Fox News Digital. “Therefore, there is no reason to take the test. … The test results would not change your medical care in any way since there is no treatment available.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
That could change if preventive treatments were approved, he added.
The study does not establish that routine blood tests prevent dementia or improve clinical outcomes.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“Many older adults with brain pathology at lower levels will never develop symptoms in their lifetime,” Jack added, noting that some people with Alzheimer’s-related pathology may also die from another cause before developing cognitive impairment.
Gn Health
